These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 2592776

  • 1. Tumor growth in vivo selects for resistance to tumor necrosis factor.
    Lattime EC, Stutman O.
    J Immunol; 1989 Dec 15; 143(12):4317-23. PubMed ID: 2592776
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Expression of the tumor necrosis factor gene in tumor cells correlates with reduced tumorigenicity and reduced invasiveness in vivo.
    Vanhaesebroeck B, Mareel M, Van Roy F, Grooten J, Fiers W.
    Cancer Res; 1991 Apr 15; 51(8):2229-38. PubMed ID: 2009541
    [Abstract] [Full Text] [Related]

  • 4. In vitro selection of a cell line for resistance to lysis by tumor necrosis factor-alpha selects for reduced tumorigenicity.
    Patek PQ, Lin Y.
    J Immunol; 1991 May 15; 146(10):3457-61. PubMed ID: 2026874
    [Abstract] [Full Text] [Related]

  • 5. Effect of ultraviolet irradiation on MCA102 tumor cell immunogenicity and sensitivity to tumor necrosis factor.
    Gorelik E, Begoviĉ M, Duty L, Herberman RB.
    Cancer Res; 1991 Mar 01; 51(5):1521-8. PubMed ID: 1997193
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro.
    Tomazic VJ, Farha M, Loftus A, Elias EG.
    J Immunol; 1988 Jun 01; 140(11):4056-61. PubMed ID: 3372997
    [Abstract] [Full Text] [Related]

  • 7. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
    Peters PM, Ortaldo JR, Shalaby MR, Svedersky LP, Nedwin GE, Bringman TS, Hass PE, Aggarwal BB, Herberman RB, Goeddel DV.
    J Immunol; 1986 Oct 15; 137(8):2592-8. PubMed ID: 3760569
    [Abstract] [Full Text] [Related]

  • 8. In vivo or in vitro selection for resistance to natural cytotoxic cell lysis selects for variants with increased tumorigenicity.
    Patek PQ, Lin Y, Collins JL, Cohn M.
    J Immunol; 1986 Jan 15; 136(2):741-5. PubMed ID: 3941271
    [Abstract] [Full Text] [Related]

  • 9. Resistance of primary CD8+ cytotoxic T lymphocytes to lysis by cytotoxic granules from cloned T cell lines.
    Nagler-Anderson C, Verret CR, Firmenich AA, Berne M, Eisen HN.
    J Immunol; 1988 Nov 15; 141(10):3299-305. PubMed ID: 2972770
    [Abstract] [Full Text] [Related]

  • 10. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M, Orosz CG, Bach FH.
    J Immunol; 1984 Jun 15; 132(6):3218-25. PubMed ID: 6202778
    [Abstract] [Full Text] [Related]

  • 11. Two discrete types of tumor necrosis factor-resistant cells derived from the same cell line.
    Vanhaesebroeck B, Van Bladel S, Lenaerts A, Suffys P, Beyaert R, Lucas R, Van Roy F, Fiers W.
    Cancer Res; 1991 May 01; 51(9):2469-77. PubMed ID: 1849793
    [Abstract] [Full Text] [Related]

  • 12. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
    Gorelik E, Gunji Y, Herberman RB.
    J Immunol; 1988 Mar 15; 140(6):2096-102. PubMed ID: 3126240
    [Abstract] [Full Text] [Related]

  • 13. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
    Nishihara K, Barth RF, Wilkie N, Lang JC, Oda Y, Kikuchi H, Everson MP, Lotze MT.
    Cancer Gene Ther; 1995 Jun 15; 2(2):113-24. PubMed ID: 7621259
    [Abstract] [Full Text] [Related]

  • 14. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.
    Cancer Res; 1993 Jan 01; 53(1):106-11. PubMed ID: 8093229
    [Abstract] [Full Text] [Related]

  • 15. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

  • 16. H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.
    Nishimura MI, Stroynowski I, Hood L, Ostrand-Rosenberg S.
    J Immunol; 1988 Dec 15; 141(12):4403-9. PubMed ID: 3264312
    [Abstract] [Full Text] [Related]

  • 17. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
    Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K.
    Cell Immunol; 2001 Dec 15; 214(2):194-200. PubMed ID: 12088418
    [Abstract] [Full Text] [Related]

  • 18. Natural cytotoxic cells and tumor necrosis factor activate similar lytic mechanisms.
    Patek PQ, Lin Y, Collins JL.
    J Immunol; 1987 Mar 01; 138(5):1641-6. PubMed ID: 3805728
    [Abstract] [Full Text] [Related]

  • 19. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 20. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.
    Kono K, Petersson M, Ciupitu AM, Wen T, Klein G, Kiessling R.
    Cancer Res; 1995 Dec 01; 55(23):5648-55. PubMed ID: 7585649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.